Thunder Bay, Ontario, Canada – December 12, 2023 – IGY Life Sciences and Immune Technologies Inc. (the “Company” or “IGY Life Sciences”) is pleased to announce results from a pilot study to evaluate the effects of Muno-IgY on immune function in healthy adult volunteers.
The study sought to explore the potential of Muno-IgYTM supplementation as an efficacious, cost-effective, safe, and non-invasive method for the immune response in healthy adults who experience Upper Respiratory Tract Infections (URTIs). The primary endpoints in the study included incidence, severity, and duration of URTI-related symptoms, all three of which decreased by approximately 60%. The 12-week study focused on healthy adults aged 35-65, further targeting populations with frequent exposure to highly populated areas, attending school or employed for at least 20 hours per week during the study.
Muno-IgYTM, a broad specific-spectrum IgY derived from egg yolks is hypothesized to support immunity and reduce the incidence of URTIs. It primarily functions in the gut by responding appropriately to pathogens in the gut and can contribute to immune homeostasis by modulating gut microflora. This can help to maintain gut health and potentially systemic immunity, which influences the immune response in the respiratory system.
Dr. Huan Nguyen, Chief Scientific Officer of IGY Life Sciences, explains “Recent and ongoing research on the gut-lung axis indicates a connection between dysbiosis in the gut microbial community and alterations in mucosal and systemic immune responses including those in the respiratory tract. A properly functioning gut mucosal lining typically acts as a protective barrier against external elements. It achieves this by maintaining a healthy balance of beneficial flora, which helps prevent harmful species from attaching to the gut lining. Conversely, an imbalance in beneficial gut flora can create conditions where pathogens may induce heightened permeability, inflammation, and potential systemic health issues that are associated with impaired immune responses to infections in the respiratory tract.”
“Upper respiratory tract infections (URTIs) pose a significant global health burden, affecting the mouth, nose, throat, larynx, and trachea,” said Terry Dyck, President, and CEO of IgY Life Sciences. “Current treatments, including antibiotics, face challenges such as antibiotic resistance and the viral nature of most URTIs. This is leading to a shift towards preventive measures and immune system strengthening. The positive trending results from this pilot study sets up well for a further study as Muno-IgYTM offers a promising approach to understanding, preventing, and treating not only infections in the gastrointestinal tract, but also upper respiratory tract infections by reinforcing intestinal wall integrity through the binding and removal of harmful pathogens. These findings suggest a potential avenue for developing innovative therapies that enhance our capacity to address emerging respiratory conditions.”
About IGY Immune Technologies and Life Sciences Inc.
IGY Life Sciences & Immune Technologies Inc. is a privately held biosciences Company specializing in the extraction, development and commercialization of broad-spectrum antibodies, or immunoglobulin (IgY), for use as OTC nutraceutical and for development of antibodies for targeted pathogens. The company was formed in 2009 to commercialize a superior proprietary process for extraction of avian immunoglobulin from chicken egg yolks. IgY is a natural antibody for which there is an existing global demand. Muno-IgYTM, derived from hen egg yolks, contains broad specific immunoglobulins Y (IgY), and emerges as a potential candidate for providing passive immunity against URTIs through modulation of microflora in the gut.
For further information:
Terry Dyck
IGY Immune Technologies & Life Sciences Inc.
Tel : 1.888.301.5437
tdyck@igylifesciences.com
SOURCE : IGY IMMUNE TECHNOLOGIES & LIFE SCIENCES INC
